HENDERSON, Nev., Oct. 19,
2023 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
announces the publication of a clinical paper1 which
shows that Volition's Nu.Q® NETs test is a promising biomarker for
the evaluation of disease severity in septic shock patients and
could play an important role in sepsis prognosis.
The 150-patient study published in Annals of Intensive Care was
led by Professor Guillaume Monneret,
Head of Clinical Immunology Laboratory at Hospices Civils de
Lyon in France.
Professor Monneret and his team used Volition's automated
nucleosome quantification assay, Nu.Q® NETs, to measure nucleosome
levels in patients with septic shock and to determine whether there
is an association with mortality.
Nu.Q® NETs is a simple, low cost and routine blood test which
can detect clinically elevated levels of NETs by identifying the
unique biomarker H3.1. Composed of decondensed chromatin, NETs play
an important role in the immune system, trapping and killing
bacteria, fungi and viruses. However, excessive production can lead
to tissue damage and, in severe cases, sepsis, organ failure, and
death.
Professor Guillaume Monneret,
Head of Clinical Immunology Laboratory at Hospices Civils de
Lyon, said:
"This was the first study to investigate both nucleosomes and
immunological parameters in septic shock. We saw a significant
elevation of nucleosomes in septic shock patients. We also found a
significant positive correlation between nucleosome levels and a
range of disease severity indicators including SOFA, SAPS II, IL–6
concentrations, and neutrophil count. Additionally, significantly
elevated nucleosome levels were independently associated with both
five and 28-day mortality, even after adjusting for typical
confounding factors such as age, severity scores, and IL-6.
"In summary, we were able to show an association of increased
circulating H3.1 nucleosomes with severity and mortality in septic
shock patients."
Remi Rabeuf, Lifecycle Leader at
Volition, said: "This is the first published data from our global
centers of excellence program and we are delighted that Professor
Monneret's findings show that Nu.Q® NETs is a promising biomarker
for the evaluation of disease severity and could support sepsis
prognosis."
There are an estimated 11 million sepsis-related deaths
worldwide each year, accounting for 20% of all global deaths.²
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's Nu.Q® technology go to:
www.volition.com
Notes:
- Haem Rahimi M; Bidar F; Lukaszewicz AC; Garnier L; Payen-Gay L;
Venet F; Monneret G, Association of pronounced Elevation of NET
formation and Nucleosome Biomarkers with Mortality in Patients with
Septic Shock, Annals of Intensive Care (2023) 13:102
- World Health Organisation October 2023
About Volition
Volition is a multi-national epigenetics company powered by
Nu.Q®, its proprietary nucleosome quantification platform. Through
its subsidiaries, Volition is developing simple, easy to use, cost
effective blood tests to help diagnose and monitor a range of
life-altering diseases including some cancers and diseases
associated with NETosis such as sepsis and COVID-19. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients but also improve their quality of life. The tests
are based on the science of Nucleosomics™, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
For more information about Volition's Nu.Q® technology go to:
www.volition.com
The contents found at the Volition and World Health Organisation
website addresses are not incorporated by reference into this
document and should not be considered part of this document. The
website addresses are included in this document as inactive textual
references only.
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
timing and launch of product sales, and the potential uses,
benefits and effectiveness of its Nucleosomics™ technology
platform, including the Nu.Q® NETs test. Volition's actual results
may differ materially from those indicated in these forward-looking
statements due to numerous risks and uncertainties, including,
without limitation, results of studies testing the efficacy of its
tests, a failure by the marketplace to accept Volition's, Nu.Q®
NETs test or other products based on its Nucleosomics™ platform;
Volition's failure to secure adequate intellectual property
protection; Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products;
Volition will face fierce competition and its intended products may
become obsolete due to the highly competitive nature of the
diagnostics and disease monitoring markets and their rapid
technological change; downturns in domestic and foreign economies;
and other risks, including those identified in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. For instance, if Volition fails
to develop and commercialize diagnostic, prognostic or disease
monitoring products, it may be unable to execute its plan of
operations. Forward-looking statements are based on current
expectations, estimates and projections about Volition's business
based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
Media Enquiries:
Louise
Batchelor/Debra Daglish,
Volition, mediarelations@volition.com +44 (0)7557 774620
View original
content:https://www.prnewswire.com/news-releases/measuring-nucleosomes-using-nuq-nets-is-a-promising-biomarker-for-septic-shock-301961849.html
SOURCE VolitionRx Limited